EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation

Chemistry and Biology

Volumn 21, Issue 11, 2014, Pages 1463-1475

  Bradley, William D ^a   Arora, Shilpi ^a   Busby, Jennifer ^a   Balasubramanian, Srividya ^a   Gehling, Victor S ^a   Nasveschuk, Christopher G ^a   Vaswani, Rishi G ^a   Yuan, Chih Chi ^a   Hatton, Charlie ^a   Zhao, Feng ^a   Williamson, Kaylyn E ^a   Iyer, Priyadarshini ^a   Méndez, Jacqui ^b   Campbell, Robert ^a   Cantone, Nico ^a   Garapaty Rao, Shivani ^a   Audia, James E ^a   Cook, Andrew S ^a   Dakin, Les A ^a   Albrecht, Brian K ^a   Harmange, Jean Christophe ^a   Daniels, Danette L ^b   Cummings, Richard T ^a   Bryant, Barbara M ^a   Normant, Emmanuel ^a   Trojer, Patrick ^a   more..

^a Department of Structural Biology   (United States)

^b PROMEGA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CPI 360; DNA METHYLTRANSFERASE; ENHANCER OF ZESTE HOMOLOG 2 INHIBITOR; LYSINE; METHIONINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VENETOCLAX; ENZYME INHIBITOR; HISTONE; MOLECULAR LIBRARY; PEPTIDE; POLYCOMB REPRESSIVE COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL ASSAY; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CELLULAR THERMAL SHIFT ASSAY; CHROMATIN IMMUNOPRECIPITATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SELECTIVITY; EC50; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GERMINAL CENTER B CELL LIKE DIFFUSE LARGE B CELL LYMPHOMA; HIGH THROUGHPUT SCREENING; HISTONE METHYLATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LIQUID CHROMATOGRAPHY; LYMPHOMA CELL; MOUSE; NONHUMAN; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KINETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; METHYLATION; MOLECULAR LIBRARY; MUTATION; NONHODGKIN LYMPHOMA; NUDE MOUSE; PATHOLOGY; THERAPEUTIC USE; TOXICITY; TUMOR CELL LINE; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HISTONES; HUMANS; KINETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; METHYLATION; MICE; MICE, NUDE; MUTATION; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 2; SMALL MOLECULE LIBRARIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84911462255     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.09.017     Document Type: Article

References (48)

1. A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, and X. Yu Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
2. W. Béguelin, R. Popovic, M. Teater, Y. Jiang, K.L. Bunting, M. Rosen, H. Shen, S.N. Yang, L. Wang, and T. Ezponda EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 23 2013 677 692
3. P. De Paepe, and C. De Wolf-Peeters Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities Leukemia 21 2007 37 43
4. E. Diaz, C.A. Machutta, S. Chen, Y. Jiang, C. Nixon, G. Hofmann, D. Key, S. Sweitzer, M. Patel, and Z. Wu Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens J. Biomol. Screen. 17 2012 1279 1292
5. K.J. Ferrari, A. Scelfo, S. Jammula, A. Cuomo, I. Barozzi, A. Stützer, W. Fischle, T. Bonaldi, and D. Pasini Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity Mol. Cell 53 2014 49 62
6. S. Garapaty-Rao, C. Nasveschuk, A. Gagnon, E.Y. Chan, P. Sandy, J. Busby, S. Balasubramanian, R. Campbell, F. Zhao, and L. Bergeron Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth Chem. Biol. 20 2013 1329 1339
7. B.A. Garcia, S. Mollah, B.M. Ueberheide, S.A. Busby, T.L. Muratore, J. Shabanowitz, and D.F. Hunt Chemical derivatization of histones for facilitated analysis by mass spectrometry Nat. Protoc. 2 2007 933 938
8. L.A. Garraway, and E.S. Lander Lessons from the cancer genome Cell 153 2013 17 37
9. A. Gonzalez-Perez, A. Jene-Sanz, and N. Lopez-Bigas The mutational landscape of chromatin regulatory factors across 4,623 tumor samples Genome Biol. 14 2013 r106
10. S. Guo, J.K. Chan, J. Iqbal, T. McKeithan, K. Fu, B. Meng, Y. Pan, W. Cheuk, D. Luo, and R. Wang EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations Clin. Cancer Res. 20 2014 3078 3086
11. I. Hidalgo, A. Herrera-Merchan, J.M. Ligos, L. Carramolino, J. Nuñez, F. Martinez, O. Dominguez, M. Torres, and S. Gonzalez Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest Cell Stem Cell 11 2012 649 662
12. E. Hodis, I.R. Watson, G.V. Kryukov, S.T. Arold, M. Imielinski, J.P. Theurillat, E. Nickerson, D. Auclair, L. Li, and C. Place A landscape of driver mutations in melanoma Cell 150 2012 251 263
13. M.J. Kiel, T. Velusamy, B.L. Betz, L. Zhao, H.G. Weigelin, M.Y. Chiang, D.R. Huebner-Chan, N.G. Bailey, D.T. Yang, and G. Bhagat Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma J. Exp. Med. 209 2012 1553 1565
14. W. Kim, G.H. Bird, T. Neff, G. Guo, M.A. Kerenyi, L.D. Walensky, and S.H. Orkin Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer Nat. Chem. Biol. 9 2013 643 650
15. C.G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S.A. Tomlins, D. Ghosh, R.G. Sewalt, A.P. Otte, and D.F. Hayes EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. USA 100 2003 11606 11611
16. S.K. Knutson, T.J. Wigle, N.M. Warholic, C.J. Sneeringer, C.J. Allain, C.R. Klaus, J.D. Sacks, A. Raimondi, C.R. Majer, and J. Song A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 8 2012 890 896
17. S.K. Knutson, N.M. Warholic, T.J. Wigle, C.R. Klaus, C.J. Allain, A. Raimondi, M. Porter Scott, R. Chesworth, M.P. Moyer, and R.A. Copeland Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. USA 110 2013 7922 7927
18. S.K. Knutson, S. Kawano, Y. Minoshima, N.M. Warholic, K.C. Huang, Y. Xiao, T. Kadowaki, M. Uesugi, G. Kuznetsov, and N. Kumar Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2 mutant non-Hodgkin lymphoma Mol. Cancer Ther. 13 2014 842 854
19. K.D. Konze, A. Ma, F. Li, D. Barsyte-Lovejoy, T. Parton, C.J. Macnevin, F. Liu, C. Gao, X.P. Huang, and E. Kuznetsova An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 ACS Chem. Biol. 8 2013 1324 1344
20. M.S. Lawrence, P. Stojanov, C.H. Mermel, J.T. Robinson, L.A. Garraway, T.R. Golub, M. Meyerson, S.B. Gabriel, E.S. Lander, and G. Getz Discovery and saturation analysis of cancer genes across 21 tumour types Nature 505 2014 495 501
21. G. Lenz, G.W. Wright, N.C. Emre, H. Kohlhammer, S.S. Dave, R.E. Davis, S. Carty, L.T. Lam, A.L. Shaffer, and W. Xiao Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc. Natl. Acad. Sci. USA 105 2008 13520 13525
22. J.G. Lohr, P. Stojanov, M.S. Lawrence, D. Auclair, B. Chapuy, C. Sougnez, P. Cruz-Gordillo, B. Knoechel, Y.W. Asmann, and S.L. Slager Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc. Natl. Acad. Sci. USA 109 2012 3879 3884
23. C.R. Majer, L. Jin, M.P. Scott, S.K. Knutson, K.W. Kuntz, H. Keilhack, J.J. Smith, M.P. Moyer, V.M. Richon, R.A. Copeland, and T.J. Wigle A687V EZH2 is a gain-of-function mutation found in lymphoma patients FEBS Lett. 586 2012 3448 3451
24. R. Malumbres, K.A. Sarosiek, E. Cubedo, J.W. Ruiz, X. Jiang, R.D. Gascoyne, R. Tibshirani, and I.S. Lossos Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas Blood 113 2009 3754 3764
25. R. Margueron, and D. Reinberg The polycomb complex PRC2 and its mark in life Nature 469 2011 343 349
26. R. Margueron, G. Li, K. Sarma, A. Blais, J. Zavadil, C.L. Woodcock, B.D. Dynlacht, and D. Reinberg Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol. Cell 32 2008 503 518
27. D. Martinez Molina, R. Jafari, M. Ignatushchenko, T. Seki, E.A. Larsson, C. Dan, L. Sreekumar, Y. Cao, and P. Nordlund Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay Science 341 2013 84 87
28. M.T. McCabe, A.P. Graves, G. Ganji, E. Diaz, W.S. Halsey, Y. Jiang, K.N. Smitheman, H.M. Ott, M.B. Pappalardi, and K.E. Allen Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) Proc. Natl. Acad. Sci. USA 109 2012 2989 2994
29. M.T. McCabe, H.M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G.S. Van Aller, Y. Liu, A.P. Graves, A.D. Iii, and E. Diaz EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492 2012 108 112
30. T.B. Miranda, C.C. Cortez, C.B. Yoo, G. Liang, M. Abe, T.K. Kelly, V.E. Marquez, and P.A. Jones DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation Mol. Cancer Ther. 8 2009 1579 1588
31. R.D. Morin, N.A. Johnson, T.M. Severson, A.J. Mungall, J. An, R. Goya, J.E. Paul, M. Boyle, B.W. Woolcock, and F. Kuchenbauer Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 42 2010 181 185
32. R.D. Morin, M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. Corbett, N.A. Johnson, T.M. Severson, R. Chiu, and M. Field Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 476 2011 298 303
33. C.G. Nasveschuk, A. Gagnon, S. Garapaty-Rao, S. Balasubramanian, R. Campbell, C. Lee, F. Zhao, L. Bergeron, R. Cummings, and P. Trojer Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2 ACS Med. Chem. Lett. 5 2014 378 383
34. J.V. Olsen, L.M. de Godoy, G. Li, B. Macek, P. Mortensen, R. Pesch, A. Makarov, O. Lange, S. Horning, and M. Mann Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap Mol. Cell. Proteomics 4 2005 2010 2021
35. W. Qi, H. Chan, L. Teng, L. Li, S. Chuai, R. Zhang, J. Zeng, M. Li, H. Fan, and Y. Lin Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. USA 109 2012 21360 21365
36. A. Rosenwald, G. Wright, W.C. Chan, J.M. Connors, E. Campo, R.I. Fisher, R.D. Gascoyne, H.K. Muller-Hermelink, E.B. Smeland, J.M. Giltnane Lymphoma/Leukemia Molecular Profiling Project The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N. Engl. J. Med. 346 2002 1937 1947
37. D. Rossi, V. Trifonov, M. Fangazio, A. Bruscaggin, S. Rasi, V. Spina, S. Monti, T. Vaisitti, F. Arruga, and R. Famà The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development J. Exp. Med. 209 2012 1537 1551
38. R. Schmitz, R.M. Young, M. Ceribelli, S. Jhavar, W. Xiao, M. Zhang, G. Wright, A.L. Shaffer, D.J. Hodson, and E. Buras Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics Nature 490 2012 116 120
39. C.J. Sneeringer, M.P. Scott, K.W. Kuntz, S.K. Knutson, R.M. Pollock, V.M. Richon, and R.A. Copeland Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. USA 107 2010 20980 20985
40. J. Son, S.S. Shen, R. Margueron, and D. Reinberg Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin Genes Dev. 27 2013 2663 2677
41. A.J. Souers, J.D. Leverson, E.R. Boghaert, S.L. Ackler, N.D. Catron, J. Chen, B.D. Dayton, H. Ding, S.H. Enschede, and W.J. Fairbrother ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 19 2013 202 208
42. G. van Haaften, G.L. Dalgliesh, H. Davies, L. Chen, G. Bignell, C. Greenman, S. Edkins, C. Hardy, S. O'Meara, and J. Teague Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat. Genet. 41 2009 521 523
43. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, and A.P. Otte The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
44. T.J. Wigle, S.K. Knutson, L. Jin, K.W. Kuntz, R.M. Pollock, V.M. Richon, R.A. Copeland, and M.P. Scott The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Lett. 585 2011 3011 3014
45. H. Xie, J. Xu, J.H. Hsu, M. Nguyen, Y. Fujiwara, C. Peng, and S.H. Orkin Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner Cell Stem Cell 14 2014 68 80
46. D.B. Yap, J. Chu, T. Berg, M. Schapira, S.W. Cheng, A. Moradian, R.D. Morin, A.J. Mungall, B. Meissner, and M. Boyle Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 117 2011 2451 2459
47. T.I. Zack, S.E. Schumacher, S.L. Carter, A.D. Cherniack, G. Saksena, B. Tabak, M.S. Lawrence, C.Z. Zhang, J. Wala, and C.H. Mermel Pan-cancer patterns of somatic copy number alteration Nat. Genet. 45 2013 1134 1140
48. B.M. Zee, R.S. Levin, B. Xu, G. LeRoy, N.S. Wingreen, and B.A. Garcia In vivo residue-specific histone methylation dynamics J. Biol. Chem. 285 2010 3341 3350